Pfizer Inc (PFE) Stock Price, Quote & News

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 212 733 2323

Website: www.pfizer.com

Address:

66 Hudson Boulevard East, New York, United States

Pfizer Feb. 27 at 3:47 PM

$PFE Pfizer and Astellas Pharma Inc. today announced positive results from the Phase 3 EV-304 clinical trial for PADCEV (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. These data will be presented today in an oral session and were featured in the press program at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco, CA. They will also be discussed with global health authorities for potential regulatory filings. Read more: https://investors.pfizer.com/Investors/News/news-details/2026/PADCEV--Keytruda-Cuts-Risk-of-Recurrence-or-Death-by-Nearly-50-in-Cisplatin-Eligible-Muscle-Invasive-Bladder-Cancer/default.aspx

1 · Reply

DailyAnalysis Feb. 27 at 3:46 PM

$PFE 1D STOCH is bottoming alongside activist investor interest. 1W CCI remains in a long-term basing pattern. 4H RSI shows steady accumulation while 30M signals suggest a low-volatility entry before a 1D breakout attempt on oncology growth. @DailyAnalysis

0 · Reply

Ed_Ng Feb. 27 at 3:45 PM

$PFE unbeatable. $60 in 2 years

0 · Reply

PFElinepfrenzy1990 Feb. 27 at 3:44 PM

$PFE akshually going up with good news? Thats very Pfizern't

1 · Reply

aba75 Feb. 27 at 3:42 PM

$PFE Moving at a snail's pace, but at least it's going up!

0 · Reply

StockNews_Live Feb. 27 at 3:00 PM

$PFE Pfizer Inc. and Astellas Pharma Inc. announced positive results from the Phase 3 EV-304 clinical trial for PADCEV (enfortumab vedotin) in combination with Keytruda (pembrolizumab) in patients with mus…

0 · Reply

STOCKPICKERTRADER Feb. 27 at 12:18 PM

$PFE used to be good news was bad, bad news was worse and couldn't catch a break and not able to show progress. Now it seems defiant to the downgrades ... interesting RBC Capital analyst Trung Huynh initiated coverage on Pfizer Inc (NYSE:PFE) with an Underperform rating and announced a price target of $25. Pfizer shares closed at $27.09 on Wednesday. See how other analysts view this stock.

1 · Reply

DailyAnalysis Feb. 27 at 11:19 AM

0 · Reply

FrankieSmilez Feb. 27 at 10:55 AM

$MRNA $PFE $NVAX Moderna's cold/flu vaccine get EU regulator recommendation.

0 · Reply

StocktwitsNews Feb. 27 at 6:54 AM

Novavax Stock Hits Over 1-Year High: Is Sanofi’s Flu-COVID Shot The Post-Pandemic Growth Driver? $NVAX $PFE https://stocktwits.com/news/equity/markets/novavax-stock-hits-over-1-year-high-sanofi-flu-covid-shot-post-pandemic-growth-driver/cZTcJaoRIRs

0 · Reply

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

Feb 26, 2026, 7:48 AM EST - 1 day ago

5 'Safer' Dividend Buys In Barron's 23 Better February Bets Than T-Bills

BBY CAG EQR FRT KEY KMI LYB

Feb 24, 2026, 2:29 PM EST - 2 days ago

U.S. FDA Grants Full Approval to Pfizer's BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

Feb 24, 2026, 7:45 AM EST - 3 days ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 23, 2026, 10:26 PM EST - 3 days ago

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 3:15 PM EST - 3 days ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Feb 23, 2026, 10:00 AM EST - 4 days ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 20, 2026, 11:47 PM EST - 6 days ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 18, 2026, 12:00 PM EST - 8 days ago

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 11:30 AM EST - 8 days ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 17, 2026, 5:42 PM EST - 9 days ago

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 6:45 AM EST - 10 days ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 13, 2026, 6:13 AM EST - 14 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

Feb 12, 2026, 8:05 AM EST - 15 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Feb 11, 2026, 6:08 PM EST - 15 days ago

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 4:06 PM EST - 15 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Feb 11, 2026, 8:56 AM EST - 16 days ago

Is Pfizer Stock Now A Value Trap?

Feb 10, 2026, 3:20 PM EST - 16 days ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 8, 2026, 10:19 PM EST - 18 days ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 6, 2026, 2:55 PM EST - 20 days ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 7:25 AM EST - 21 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

Feb 6, 2026, 6:45 AM EST - 21 days ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 5, 2026, 7:09 PM EST - 21 days ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 3, 2026, 3:00 PM EST - 23 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 2:02 PM EST - 23 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 1:27 PM EST - 23 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Feb 3, 2026, 12:00 PM EST - 23 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 11:56 AM EST - 23 days ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:17 AM EST - 23 days ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Feb 3, 2026, 10:15 AM EST - 24 days ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 8:50 AM EST - 24 days ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:17 AM EST - 24 days ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 7:28 AM EST - 24 days ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:21 AM EST - 24 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:18 AM EST - 24 days ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:02 AM EST - 24 days ago

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Feb 3, 2026, 6:57 AM EST - 24 days ago

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Feb 3, 2026, 6:50 AM EST - 24 days ago

Pfizer beats fourth-quarter profit estimates on strong drug demand

Feb 3, 2026, 6:45 AM EST - 24 days ago

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3, 2026, 6:45 AM EST - 24 days ago

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Feb 3, 2026, 6:40 AM EST - 24 days ago

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Feb 2, 2026, 8:42 AM EST - 25 days ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

SNY

Feb 2, 2026, 1:01 AM EST - 25 days ago

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Jan 31, 2026, 3:47 AM EST - 27 days ago

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

BBY CAG EQR FRT KEY LYB MAA

Jan 30, 2026, 10:31 AM EST - 4 weeks ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 7:30 AM EST - 4 weeks ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Jan 29, 2026, 9:00 AM EST - 4 weeks ago

Pfizer: A High-Yield Pharma At A Turning Point

Jan 27, 2026, 4:52 PM EST - 4 weeks ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Jan 27, 2026, 7:40 AM EST - 4 weeks ago

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 6:02 AM EST - 4 weeks ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Pfizer Feb. 27 at 3:47 PM

1 · Reply

DailyAnalysis Feb. 27 at 3:46 PM

0 · Reply

Ed_Ng Feb. 27 at 3:45 PM

$PFE unbeatable. $60 in 2 years

0 · Reply

PFElinepfrenzy1990 Feb. 27 at 3:44 PM

$PFE akshually going up with good news? Thats very Pfizern't

1 · Reply

aba75 Feb. 27 at 3:42 PM

$PFE Moving at a snail's pace, but at least it's going up!

0 · Reply

StockNews_Live Feb. 27 at 3:00 PM

0 · Reply

STOCKPICKERTRADER Feb. 27 at 12:18 PM

1 · Reply

DailyAnalysis Feb. 27 at 11:19 AM

0 · Reply

FrankieSmilez Feb. 27 at 10:55 AM

$MRNA $PFE $NVAX Moderna's cold/flu vaccine get EU regulator recommendation.

0 · Reply

StocktwitsNews Feb. 27 at 6:54 AM

0 · Reply

Mmoney2424 Feb. 27 at 4:42 AM

$NVAX squeezing 🚨 watch Watch: Break and close above recent high 12.50–$13 Volume spike over current 20–25M range If that happens, shorts trapped above $15–$20 could panic $AZN $LLY $JNJ $PFE

0 · Reply

DragonAlgo Feb. 27 at 2:25 AM

🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-02-27 | Strike: $26.50 | Type: CALL Option Plan (premium): Entry: $0.63 Stop: $0.45 TP1: $0.82 TP2: $1.07 TP3: $1.51 Volatility regime is active. 🔗 https://dragonalgo.com

1 · Reply

funnymoney90210 Feb. 27 at 12:15 AM

$PFE this is about to blast off. Get in before it goes to $53

2 · Reply

IGotYouRides Feb. 26 at 11:21 PM

$NVAX $PFE

0 · Reply

TheWinningStock Feb. 26 at 11:03 PM

$PFE .....🤣

0 · Reply

dbears729 Feb. 26 at 10:43 PM

$LENZ lots of Vizz-ability for Lenz at the TD Cowen 46th Annual Health Care Conference with the big boys on Monday. Yoooolo $MRK $PFE

1 · Reply

MikeOxBigg Feb. 26 at 10:38 PM

$NVAX $PFE The company successfully signed a new agreement with Pfizer for MatrixM, which could potentially generate BILLIONS in revenue through milestones and royalties. **BILLIONS in revenue through Pfizer alone.**

0 · Reply

MarcoFla99 Feb. 26 at 9:37 PM

$PFE Hearing whispers the Great Greek is about to make another acquisition....This one will pay PFE huge dividends. JMHO

2 · Reply

Tom2424 Feb. 26 at 9:29 PM

$VXRT $MRNA $PFE $SNY From a forensic perspective, the convergence of "workplace complaints" against a high-ranking regulator (Prasad) and the financial interests of transition-linked stakeholders indicates a "Multi-Vector Regulatory Capture." The Clinical-Financial Conflict: An insistence on unblinding the Sentinel (N=400) data and exposing the "Antigenic Shunt" poses a systemic risk to short positions and the "synthetic liquidity" structures managed by primary market makers. If the data is released "cleanly" and "shortly" (as management recently suggested), the resulting price discovery would likely bypass the controlled "Take-Under" environment preferred by certain admin.- actors. By triggering an external probe into leadership, these interests aim to create a "Compliance Fog." This maneuver serves to delay the publication of the 8% Efficacy Delta, providing a window to close FTDs or finalize an acquisition at suppressed levels before the FDA formally validates the VAAST™ platform.

1 · Reply

srvrtest Feb. 26 at 8:33 PM

$PFE $MRNA $BNTX $NVAX im not shorting but seeing some connections with the meeting. Want to hear other's thoughts. https://www.lee.senate.gov/2026/2/lee-paul-introduce-end-to-vaccine-carveouts https://seekingalpha.com/news/4557989-cdc-advisors-to-discuss-covid-vaccine-injuries-long-covid?mailingid=44377248&messageid=2900&position=rta_news_bankr_fullrollout_hysa_main_0_title&serial=44377248.4558&source=email_2900&utm_campaign=rta-stock-news&utm_content=link-1&utm_source=seeking_alpha&utm_term=44377248.4558

0 · Reply

IGotYouRides Feb. 26 at 8:19 PM

$NVAX $MRNA $LLY $JNJ $PFE Looks extremely undervalued I wouldn't wait to grabs shares won't be this low for long! Partnership with Pfizer........ They have a Gold standard Vaccine

0 · Reply

srvrtest Feb. 26 at 7:53 PM

$PFE Reason for PFE puts in Mar 20 Mar 27 - , everyone knows the internal other than us beforehand. Going to 24$ it seems """ The CDC has added topics on COVID-19 vaccine injuries and long COVID to the agenda of the next meeting of its vaccine advisors, also known as the Advisory Committee on Immunization Practices (ACIP) in March. The meeting, which was initially scheduled to take place from Feb. 25 to 27, was postponed to Mar. 18–Mar. 19 this week, after several leading medical groups in the U.S. filed a lawsuit seeking a ruling to block the CDC. COVID-19 vaccine developers: Pfizer (PFE)/BioNTech (BNTX), Moderna (MRNA), and Novavax (NVAX).

0 · Reply

Market Cap	154.03B
Revenue (ttm)	62.58B
Net Income (ttm)	7.77B
EPS (ttm)	N/A
PE Ratio	8.38
Forward PE	9.11
Profit Margin	12.42%
Debt to Equity Ratio	0.66

Volume	30,508,200
Avg Vol	48,563,391
Day's Range	N/A - N/A
Shares Out	5.69B
Stochastic %K	47%
Beta	0.47
Analysts	Sell
Price Target	$28.44